Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.

ENTAยทNASDAQ

$12.03

-6.6%
HealthcareBiotechnology

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

At a Glance

Live Snapshot
Market Cap$279.30M
EPS-3.8400
P/E Ratio-3.12
Earnings Date08/10/2026

No Dividend Yield Data

ENTA has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

ENTA has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

ENTA has not reported any net dividends paid values in the available annual periods.

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. Dividend History

ENTA ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

ENTA Dividend Payment History

ENTA ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
enta

Enanta Pharmaceuticals, Inc. Payout Ratio Analysis

ENTA ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-81.89M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.